- Previous Close
0.0000 - Open
0.5500 - Bid --
- Ask --
- Day's Range
0.5500 - 0.5500 - 52 Week Range
0.5500 - 0.5500 - Volume
25,000 - Avg. Volume
0 - Market Cap (intraday)
643.126M - Beta (5Y Monthly) 0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 29, 2020
- 1y Target Est
--
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, sells, and markets pharmaceutical products in the therapeutic areas of anti-infection, endocrine and metabolic, and other diseases in the People's Republic of China. It manufactures and sells active pharmaceutical ingredients; researches and develops pharmaceutical products, and medical devices and drugs, as well as biotechnology; and provides marketing and medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. The company's products are Kewei, Oumeining, Xinhaining, Ertongshu, and Xining. It has a strategic cooperation framework agreement with Jointown Pharmaceutical Group Co., Ltd., as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. operates as a subsidiary of Sunshine Lake Pharma Co., Ltd.
www.hec-changjiang.com4,618
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: YIHCF
View MorePerformance Overview: YIHCF
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YIHCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YIHCF
View MoreValuation Measures
Market Cap
1.34B
Enterprise Value
1.45B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
31.66%
Return on Assets (ttm)
14.16%
Return on Equity (ttm)
26.50%
Revenue (ttm)
6.29B
Net Income Avi to Common (ttm)
1.99B
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.69B
Total Debt/Equity (mrq)
32.88%
Levered Free Cash Flow (ttm)
1.09B